As of 2025-11-13, the Intrinsic Value of Vifor Pharma AG (VIFN.SW) is 136.70 CHF. This VIFN.SW valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 166.15 CHF, the upside of Vifor Pharma AG is -17.70%.
The range of the Intrinsic Value is 82.41 - 547.24 CHF
Based on its market price of 166.15 CHF and our intrinsic valuation, Vifor Pharma AG (VIFN.SW) is overvalued by 17.70%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 82.41 - 547.24 | 136.70 | -17.7% |
| DCF (Growth 10y) | 117.90 - 774.04 | 194.88 | 17.3% |
| DCF (EBITDA 5y) | 78.18 - 155.60 | 115.50 | -30.5% |
| DCF (EBITDA 10y) | 98.39 - 193.75 | 142.42 | -14.3% |
| Fair Value | 55.63 - 55.63 | 55.63 | -66.52% |
| P/E | 49.22 - 148.10 | 93.93 | -43.5% |
| EV/EBITDA | 75.61 - 153.33 | 114.44 | -31.1% |
| EPV | 62.95 - 87.92 | 75.43 | -54.6% |
| DDM - Stable | 32.61 - 300.42 | 166.51 | 0.2% |
| DDM - Multi | 118.80 - 776.62 | 199.57 | 20.1% |
| Market Cap (mil) | 10,781.69 |
| Beta | 1.61 |
| Outstanding shares (mil) | 64.89 |
| Enterprise Value (mil) | 10,391.69 |
| Market risk premium | 5.10% |
| Cost of Equity | 5.72% |
| Cost of Debt | 4.25% |
| WACC | 5.62% |